. Suspicious lesions were reported on both TRUS (hypoechoic lesion (HEL)) and MRI (!PI-RADS v2 score 3) in 69% of patients. More lesions per patient were found on MRI compared to TRUS (1.49 vs. 1.03, p<0.01). PI-RADS 3, 4, and 5 MRI lesions were seen as HEL on TRUS in 51%, 69%, and 85% of patients, respectively. PCa and clinically significant PCa were detected in 84% and 5% of PI-RADS 3 lesions, 80% and 49% of PI-RADS 4 lesions, and 93% and 79% of PI-RADS 5 lesions, respectively. SBx detected the highest overall Gleason score or was equivalent to MBx/TBx in 135 patients (67%). The highest overall Gleason score was detected in 17 patients (8%) by TBx, and in 13 patients (6%) by MBx. In 36 patients (18%) no PCa was found by any biopsy method.
INTRODUCTION AND OBJECTIVES: Underestimation of
Gleason score after prostate biopsy is one of unsolved problems of Prostate Cancer (PC) diagnosis. Patients considered to be low risk PC undergo active surveillance, refuse from pelvic lymph nodes dissection during radical prostatectomy and experimental focal techniques. Underestimation of Gleason score results in high rates of low risk PC treatment failures. Opportunity of co-registration of multiparametric Magnetic Resonance Imaging (MRI) and Ultra Sound (US) images to perform targeted biopsy of index lesion is new option for clinically significant PC detection. The purpose of our study is to evaluate if MRI-US Fusion Biopsy (FB) can decrease the upgrading rate after radical prostatectomy comparing with Systemic Biopsy (SB).
METHODS: We retrospectively analyzed single clinic database for patients who underwent MRI-US FB followed by radical prostatectomy in 2016 to 2018. We performed MRI-US FB in every patients with PSA!2 ng/ml or positive digital rectal examination and if multiparametric MRI revealed lesions PIRADS!3. The control group consisted of patients who underwent systematic 12-21 core biopsy followed by prostatectomy in 2015-2016, before the implementation of MRI-US FB in our clinic. Upgrade of Gleason score case was defined if final Gleason score was at least 1 point higher than after biopsy. The number of patients with Gleason upgrade after radical prostatectomy in both groups were compared.
RESULTS: Included in study were 114 patients, 54 patients in MRI-US FB group and 60 patients in SB group. Mean patient age was 62.4 AE 2.1 years in MRI-US FB group and 64.4 AE 3.1 years in SB group. Mean PSA was 7.1 AE 2.3 ng/ml in MRI-FB group and 7.8 AE 3.2 ng/ml in SB group. Of 54 patients of MRI-US FB group in 12 (22%) Gleason score upgrade was revealed after radical prostatectomy while of 60 patients of SB group upgrade was revealed in 27 (45%) patients p 0.05.
CONCLUSIONS: MRI-US FB significantly decreases the risk of upgrading after radical prostatectomy by better finding of index lesion. More precise stratification of patients on risk groups could make us more confident in choosing way of PC management. Implementation of MRI-US FB can result in less low risk PC treatment failures. (SB) has been widely performed as the standard of care concurrently with MRI-targeted biopsy (TB) for prostate cancer (PC) diagnosis although several studies have shown that TB has similar or higher detection rates of significant cancer (SC) than SB. The aim is to clarify who benefits additionally from concurrent SB in SC detection.
METHODS: Between Jun 2017 and Oct 2018, 194 consecutive patients with a clinical suspicion of PC who underwent 3T multiparametric MRI followed by TB and 12-core SB using an MRIultrasound fusion system (UroNav, Invivo) were enrolled. MRI was centrally assessed using PIRADS v2. Men without PIRADS !3 lesions were excluded. In TB, a maximum of 3 suspicious regions of interest (ROI) were chosen as targets and 3 cores were taken for each target. The index target was defined as a lesion with the highest PIRADS score (iPIRADS). SC was defined as cancer with ISUP grade group !2 and/or maximum cancer length >5 mm. According to iPIRADS, detection rates of SC on TB and SB were investigated. Spatial relations between target sites and SB sampling sites were analyzed using 3-D image processing and segmentation software (DynaCAD, Invivo).
RESULTS: In total, iPIRADS !3 was identified in 171 men CONCLUSIONS: A majority of SC (87% [99/114]) detected by the combination biopsy is detectable by TB alone. However, men with iPIRADS 4 lesions acquire larger benefits from concurrent SB because more SC outside the ROI of TB is detected by SB compared to the other scores. Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e427
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